Abstract
Purpose :
We evaluated the effects of Mikeruna®, a combined glaucoma eye drop solution containing latanoprost and carteolol.
Methods :
We studied 152 eyes of 95 patients with primary open angle glaucoma, primary angle closure glaucoma, and normal tension glaucoma. These patients had initially used a combination of prostaglandin and β blocker drugs such as Xalacom®, Duo Trav®, and Tapcom®; for the study, patients changed to Mikeruna®, a compound drug comprising a prostaglandin (latanoprost) and carteolol. We evaluated the lowering effect and complications of Mikeruna® and compared the results with those of other drug combinations. Intraocular pressure (IOP) was measured monthly, and the average value of three measurements before and after switching to Mikeruna® was adopted. To eliminate differences among examiners, all measurements were taken with the same intraocular pressure-measuring instrument.
Results :
In the case of change of Xalacom® (Latanoprost Timolol maleate, Pfizer Inc., NY, U.S.A) to Mikeruna®, intraocular pressure decreased from 11.77 mmHg to 11.18 mmHg (n=90). The change from Duo Trav® (Travoprost Timolol maleate, Alcon Inc., Hünenberg, Swiss) to Mikeruna® lowered IOP from 14.62 mmHg to 14.10 mmHg (n=56). The switch from Tapcom® (Tafluprost Timolol maleate, Santen Pharmaceutical Co., Ltd., Tokyo, Japan) to Mikeruna® lowered IOP from 14.47 mmHg to 13.37 mmHg (n=6). Use of Mikeruna® did not result in obvious complications.
Conclusions :
here was no significant difference in ocular lowering effect on changing glaucoma medication to Mikeruna®. Nevertheless, there were no increases in complications, and patients experienced easier instillation and eye drop comfort.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.